Enliven Therapeutics, Inc.
ELVN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1,045 | $985 | $1,122 |
| - Cash | $102 | $119 | $102 | $124 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $926 | $884 | $998 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$20 | -$29 | -$32 | -$27 |
| % Margin | – | – | – | – |
| Net Income | -$20 | -$25 | -$29 | -$23 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.32 | -0.49 | -0.57 | -0.46 |
| % Growth | 34.7% | 14% | -23.9% | – |
| Operating Cash Flow | -$13 | -$17 | -$24 | -$17 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$13 | -$17 | -$24 | -$17 |